Big pharma, Partnering, Pharma

Sanofi and Adimab enter multi-target discovery pact

Posted on 08 February 2015

Tags: , ,

Adimab announced a multi-target discovery and optimization collaboration with Sanofi.

Adimab will use its proprietary platform to generate bispecific molecules against multiple targets.

Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


Adimab and Sanofi have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics against multiple targets.

For each project, the agreement grants Sanofi the right to research antibodies and bispecifics generated during the collaboration for potential use as therapeutic products.

Adimab will receive an undisclosed upfront payment, research fees and technical milestones.

In addition, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics generated during the collaboration.

If Sanofi exercises its option for a particular therapeutic lead, Adimab would receive license fees, clinical milestones and royalties on product sales.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply